Combination Treatment with Theranostic Nanoparticles for Glioblastoma Sensitization to TMZ

Molecular Imaging and Biology

Volumn 16, Issue 5, 2014, Pages 680-689

  Yoo, Byunghee ^a   Ifediba, Marytheresa A ^a,b   Ghosh, Subrata ^a   Medarova, Zdravka ^a   Moore, Anna ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Chlorotoxin; Glioblastoma multiforme; MRI; Nanoparticle; siRNA; Targeting; Temozolomide; Theranostic

Indexed keywords

EID: 84897280663     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0734-3     Document Type: Article

References (49)

1. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
3. Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585–2597
4. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874
5. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
6. Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119–6129
7. Dumenco LL, Allay E, Norton K, Gerson SL (1993) The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science 259:219–222
8. Kaina B, Fritz G, Mitra S, Coquerelle T (1991) Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12:1857–1867
9. Pistollato F, Abbadi S, Rampazzo E et al (2010) Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28:851–862
10. Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199
11. Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933–4938
12. Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51
13. Yoshino A, Ogino A, Yachi K et al (2010) Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol 36:1367–1377
14. Chinnasamy N, Rafferty JA, Hickson I et al (1997) O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89:1566–1573
15. Fairbairn LJ, Watson AJ, Rafferty JA et al (1995) O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol 23:112–116
16. Kato T, Natsume A, Toda H et al (2010) Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther 17:1363–1371
17. Kumar M, Yigit M, Dai G et al (2010) Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res 70:7553–7561
18. Medarova Z, Pham W, Farrar C et al (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13:372–377
19. Kumar M, Medarova Z, Pantazopoulos P et al (2010) Novel membrane-permeable contrast agent for brain tumor detection by MRI. Magn Reson Med 63:617–624
20. DeBin JA, Strichartz GR (1991) Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon 29:1403–1408
21. Lyons SA, O'Neal J, Sontheimer H (2002) Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 39:162–173
22. Deshane J, Garner CC, Sontheimer H (2003) Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 278:4135–4144
23. Veiseh M, Gabikian P, Bahrami SB et al (2007) Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 67:6882–6888
24. Mamelak AN, Rosenfeld S, Bucholz R et al (2006) Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 24:3644–3650
25. Shen S, Khazaeli MB, Gillespie GY, Alvarez VL (2005) Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice. J Neurooncol 71:113–119
26. Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H (1998) Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 58:4871–4879
27. Kievit FM, Veiseh O, Fang C et al (2010) Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 4:4587–4594
28. Lee MJ, Veiseh O, Bhattarai N et al (2010) Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One 5:e9536
29. Sun C, Fang C, Stephen Z et al (2008) Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine 3:495–505
30. Veiseh O, Kievit FM, Fang C et al (2010) Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 31:8032–8042
31. Veiseh O, Sun C, Fang C et al (2009) Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood–brain barrier. Cancer Res 69:6200–6207
32. Veiseh O, Sun C, Gunn J et al (2005) Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 5:1003–1008
33. Fu YJ, Yin LT, Liang AH et al (2007) Therapeutic potential of chlorotoxin-like neurotoxin from the Chinese scorpion for human gliomas. Neurosci Lett 412:62–67
34. McFerrin MB, Sontheimer H (2006) A role for ion channels in glioma cell invasion. Neuron Glia Biol 2:39–49
35. Watson AJ, Margison GP (1999) O (6)-Alkylguanine-DNA Alkyltransferase Assay. Methods Mol Med 28:167–178
36. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN (2011) Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol Chapter 14:Unit 14 16.
37. Akinc A, Thomas M, Klibanov A, Lanfer R (2005) Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7:657–663
38. Wang P, Yigit MV, Ran C et al (2012) A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection. Diabetes 61:3247–3254
39. Wang P, Yigit M, Medarova Z et al (2011) Combined small interfering RNA therapy and in vivo magnetic resonance imaging in islet transplantation. Diabetes 60:565–571
40. Hobbs SK, Monsky WL, Yuan F et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95:4607–4612
41. Chahal M, Xu Y, Lesniak D et al (2010) MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 12:822–833
42. Cordier D, Forrer F, Kneifel S et al (2010) Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P—results from a phase I study. J Neurooncol 100:129–136
43. Jenkinson MD, Smith TS, Haylock B et al (2010) Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. J Neurooncol 99:103–113
44. Oshiro S, Tsugu H, Komatsu F et al (2006) Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res 26:4027–4032
45. Moore A, Marecos E, Bogdanov A Jr, Weissleder R (2000) Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214:568–574
46. Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:322–333
47. Stein GH (1979) T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J Cell Physiol 99:43–54
48. Yin D, Xie D, Hofmann WK et al (2003) DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog 36:23–31
49. Kesavan K, Ratliff J, Johnson EW et al (2010) Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem 285:4366–4374